Screening novel, potent multidrug-resistant modulators from imidazole derivatives

Oncology Research

Volumn 14, Issue 7-8, 2004, Pages 355-362

  Chen, Li Ming ^a   Wu, Xing Ping ^a   Ruan, Ji Wu ^a   Liang, Yong Ju ^a   Ding, Yan ^a   Shi, Zhi ^a   Wang, Xiu Wen ^a   Gu, Lian Quan ^a   Fu, Li Wu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Doxorubicin; Imidazole; Multidrug resistance; P glycoprotein; Vincristine

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DOXORUBICIN; FG 020301; FG 020305; FG 020307; FG 020308; FG 020318; FG 020326; FG 020327; IMIDAZOLE DERIVATIVE; RHODAMINE 123; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SPECTROFLUOROMETRY;

EID: 4043053670     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/0965040041292378     Document Type: Article

References (25)

1. Lee, C. H. Reversing agents for ATP-binding cassette (ABC) transporters: Application in modulating multidrug resistance (MDR). Curr. Med. Chem. Anti-Cancer Agents 4(1):43-52; 2004.
2. Cole, S. P.; Deeley, R. G. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20(11):931-940; 1998.
3. Laurencot, C. M.; Scheffer, G. L.; Scheper, R. J.; Shoemaker, R. H. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int. J. Cancer 72(6):1021-1026; 1997.
4. Doyle, L. A.; Ross, D. D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22(47):7340-7358; 2003.
5. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967-1972; 1981.
6. Hesselink, D. A.; van Schaik, R. H.; van der Heiden, I. P.; van der Werf, M.; Gregoor, P. J.; Lindemans, J.; Weimar, W.; van Gelder, T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74(3):245-254; 2003.
7. Watanabe, T.; Tsuge, H.; Oh-Hara, T.; Naito, M.; Tsuruo, T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol. 34(2):235-241; 1995.
8. Mistry, P.; Plumb, J.; Eccles, S.; Watson, S.; Dale, I.; Ryder, H.; Box, G.; Charlton, P.; Templeton, D.; Bevan, P. B. In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. Br. J. Cancer 79(11-12):1672-1678; 1999.
9. Rowinsky, E. K.; Smith, L.; Wang, Y. M.; Chaturvedi, P.; Villalona, M.; Campbell, E.; Aylesworth, C.; Eckhardt, S. G.; Hammond, L.; Kraynak, M.; Drengler, R.; Stephenson, J., Jr.; Harding, M. W.; Von Hoff, D. D. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J. Clin. Oncol. 16(9):2964-2976; 1998.
10. Nokihara, H.; Yano, S.; Nishioka, Y.; Hanibuchi, M.; Higasida, T.; Tsuruo, T.; Sone, S. A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells. Jpn. J. Cancer Res. 92(7):785-792; 2001.
11. Sparreboom, A.; Planting, A. S.; Jewell, R. C.; van der Burg, M. E.; van der Gaast, A.; de Bruijn, P.; Loos, W. J.; Nooter, K.; Chandler, L. H.; Paul, E. M.; Wissel, P. S.; Verweij, J. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 10(8):719-728; 1999.
12. Sikic, B. I. Pharmacologic approaches to reversing multidrug resistance. Semin. Hematol. 34(4 Suppl. 5):40-47; 1997.
13. Gruber, A.; Bjorkholm, M.; Brinch, L.; Evensen, S.; Gustavsson, B.; Hedenus, M.; Juliusson, G.; Lofvenberg, E.; Nesthus, I.; Simonsson, B.; Sjo, M.; Stenke, L.; Tangen, J. M.; Tidefelt, U.; Uden, A. M.; Paul, C.; Liliemark, J. A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Leuk. Res. 27(4):323-328; 2003.
14. Tranchand, B.; Catimel, G.; Lucas, C.; Sarkany, M.; Bastian, G.; Evene, E.; Guastalla, J. P.; Negrier, S.; Rebattu, P.; Dumortier, A.; Foy, M.; Grossin, F.; Mazier, B.; Froudarakis, M.; Barbet, N.; Clavel, M.; Ardiet, C. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Cancer Chemother. Pharmacol. 41(4)281-291; 1998.
15. Gate, L.; Couvreur, P.; Nguyen-Ba, G.; Tapiero, H. N-methylation of anthracyclines modulates their cytotoxicity and pharmacokinetics in wild type and multidrug resistant cells. Biomed. Pharmacother. 57(7):301-308; 2003.
16. Callies, S.; de Alwis, D. P.; Harris, A.; Vasey, P.; Beijnen, J. H.; Schellens, J. H.; Burgess, M.; Aarons, L. A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar trihydrochloride (LY335979). Br. J. Clin. Pharmacol. 56(1):46-56; 2003.
17. Mistry, P.; Stewart, A. J.; Dangerfield, W.; Okiji, S.; Liddle, C.; Bootle, D.; Plumb, J. A.; Templeton, D.; Charlton, P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 61(2):749-758; 2001.
18. Fu, L. W.; Zhang, Y. M.; Liang, Y. J.; Yang, X. P.; Pan, Q. C. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur. J. Cancer 38(3):418-426; 2002.
19. Fu, L. W.; He, L. R.; Liang, Y. J.; Chen, L. M.; Xiong, H. Y.; Yang, X. P.; Pan, Q. C. Experimental chemotherapy against xenografts derived from multidrug resistant KBv200 cells and parental drug-sensitive KB cells in nude mice by annonaceous acetogenin 89-2. Yao Xue Xue Bao 38(8):565-570; 2003.
20. Fu, L.; Liang, Y.; Deng, L.; Ding, Y.; Chen, L.; Ye, Y.; Yang, X.; Pan, Q. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein- mediated multidrug resistance. Cancer Chemother. Pharmacol. 53(4)349-356; 2004.
21. Kobayashi, Y.; Yamashiro, T.; Nagatake, H.; Yamamoto, T.; Watanabe, N.; Tanaka, H.; Shigenobu, K.; Tsuruo, T. Expression and function of multidrug resistance P-glycoprotein in a cultured natural killer cell-rich population revealed by MRK16 monoclonal antibody and AHC-52. Biochem. Pharmacol. 48(8):1641-1646; 1994.
22. Naito, S.; Koike, K.; Ono, M.; Machida, T.; Tasaka, S.; Kiue, A.; Koga, H.; Kumazawa, J. Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance. Oncol. Res. 10(3):123-132; 1998.
23. Wang, R. B.; Kuo, C. L.; Lien, L. L.; Lien, E. J. Structure-activity relationship: Analyses of p-glycoprotein substrates and inhibitors. J. Clin. Pharmacol. Ther. 28(3): 203-228; 2003.
24. Tsuruo, T.; Naito, M.; Tomida, A.; Fujita, N.; Mashima, T.; Sakamoto, H.; Haga, N. Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal. Cancer Sci. 94(1):15-21; 2003.
25. Croce, A. C.; Supino, R.; Lanza, K. S.; Locatelli, D.; Baglioni, P.; Bottiroli, G. Photosensitizer accumulation in spontaneous multidrug resistant cells: A comparative study with Rhodamine 123, Rose Bengal acetate and Photofrine. Photochem. Photobiol. Sci. 1(1):71-78; 2002.